Policy, Payment & Practice -> Health Economics D-PO01 - Featured Poster Session (ID 11) Poster

D-PO01-073 - Reduced Healthcare Utilization And Cost With Atrial Fibrillation Catheter Ablation In Patients With Heart Failure (ID 74)

  M.E. Field: Research (Contracted Grants for PIs and Named Investigators only) - EPIX Therapeutics; Biosense Webster, Inc..


Background: Catheter ablation (CA) is an effective treatment for patients with atrial fibrillation (AF) and heart failure (HF). However, there is limited information on the impact of CA on healthcare utilization among patients with AF-HF.
Objective: To compare healthcare utilization and cost among AF-HF patients in the 1-year period before and after CA.
Methods: Patients (age ≥ 19 years) undergoing CA with a primary or secondary diagnosis of AF-HF between 2012-2018 were identified in the Optum database. Co-primary outcomes were inpatient admissions, emergency department (ED) and office visits, and cardioversion. Cost associated with healthcare utilization was compared for the 1-year period before and after CA. McNemar’s test and Wilcoxon signed-rank test were used to assess the proportion and mean changes in outcomes pre- and post-CA. Sensitivity analysis was performed by excluding 3 months pre-and-post CA.
Results: In 1,570 patients included, there was a 64% reduction in the proportion with AF-related admissions, 22% reduction in HF-related admissions, 51% reduction in AF-related ED visits, and 70% reduction in cardioversions in the 1-year post- vs pre-CA period. However, a 4.5% increase the proportion of patients with AF-related office visits was seen. Mean AF-related inpatient admission cost per patient decreased by 39% in the 1-year post- vs pre-CA period. Results were similar after excluding the 3-months pre- and post-CA.
Conclusion: CA for AF among HF patients led to a significant reduction in the healthcare utilization and cost.